Tag Archives: Edge

Forex Trading Articles

Low Latency Your Forex Trading Edge

Latency is defined as the delay in the time it takes for data to travel from point A to point B. In the case of Forex trading, this equates to the distance between your broker and their respective liquidity sources.

Latency tends to be one of the most overlooked aspects of Forex trading. From a trader’s perspective the focus has always been on the front end trading software. However, reductions in latency should be one of the most important considerations in selecting a Forex broker. It is essential that an STP broker that connects to various liquidity sources lessen the time that trade messages takes to reach those sources of liquidity.

The Case for Colocation

As is the case with many businesses, a major key to success is “location, location, location”. Numerous studies have shown that the most effective way to limit latency is to make sure the physical location of the broker’s servers are in close physical proximity to the data source. DivisaFX accomplishes this by locating their servers within the same facility where Currenex hosts their servers. This means that trade messages travel the shortest distance possible and offer clients precious milliseconds advantage over other brokers.

Many algorithmic and high frequency traders take advantage of the improved execution times by hosting their trading system in a collocation with their broker. Through a partnership with TradeSpotFX, traders can now use the VPS (Virtual Private Server) service to reduce latency and maximize the effectiveness of their expert advisor or other automated trading system they might use.

Another benefit of server collocation is security. Financial institutions are required by law to adhere to the strictest levels of security and data integrity. They must also maintain server uptime of 99.99% so numerous backups are implemented to insure uninterrupted trading for clients of DivisaFX.

Market Analysis

US Cholesterol Lowering Agents Market On The Edge of a Patent Cliff

With nine drugs expected to lose their patents between 2011 and 2016, the US Cholesterol Lowering Agents (Dyslipidemia) Market currently stands at the edge of a major patent cliff. IMARC Group, one of the world’s leading research and advisory firms, expects in its new report” US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff” that despite a strong performance of Crestor (Rosuvatation), the avalanche of patent expiries and a thin drug pipeline will erode this market of sales worth more than US$ 8.7 Billion in the next six years.

IMARC’s new report entitled “US Cholesterol Lowering Agents Market: On the Edge of a Patent Cliff” provides an analytical and statistical insight into the US Cholesterol Lowering agents Market. The study that has been undertaken using both desk-based as well as qualitative primary research has analyzed the following aspects of this market:

Key Aspects Analyzed:

Understanding the Epidemiology of Dyslipidemia in the US:

Focus of the Analysis:

  • Current and future size of the dyslipidemia patient pool
  • Current and future prevalence of dyslipidemia
  • Current and future diagnosis rates for dyslipidemia
  • Current and future drug treatment rates for dyslipidemia

Comprehensive Evaluation of the US Cholesterol Lowering Agents Market:

Classes Covered: Statins, Fixed Dose Combinations, Ion Exchange Resins, Fibrates, Other Cholesterol Triglyceride Regulators, Omega-3 Acid Ethyl Esters and CETP Inhibitors

Molecules Covered: Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin, Fluvastatin, Lovastatin, Pitavastatin, Ezetimibe/Simvastatin, ER Niacin/Simvastatin, Atorvastatin/Amlodipine, ER Naicin/Laropiprant, Ezetimibe/Atorvastatin, ER Niacin/Laropiprant/Simvastatin, Colesevelam, Cholestyramine, Colestipol, Fenofibrate, Fenofibric Acid, Gemfibrozil, Dalcetrapib, Anacetrapib

Focus of the Analysis for Each Class & Molecule:

  • Drug Overview
  • Historical Sales
  • Key Players and Brands in the Market
  • Patent Expiries and Generic Launch
  • Sales Forecast

Comprehensive Evaluation of Generic Opportunities in the US Cholesterol Lowering Agents Market:

  • Historical Patent Expiries and the Evolution of Generic Drugs
  • Historical Value and Volume share of Brands and Generics
  • Future Patent Expiries and Generic Launches
  • Value and Volume Forecasts for Brands and Generics

Information Sources:

Information has been sourced from both primary and secondary sources:

  • Primary sources include industry surveys and face to face/telephone interviews with industry experts.
  • Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, industry portals, government sources and access to more than 4000 paid databases.

Table of Contents:

1. Research Methodology & Market Definitions

2. Executive Summary

3. Epidemiology

3.1 Prevalence of Dyslipidemia

3.2 Diagnosis & Drug Treatment Rates

4. The US Cholesterol Lowering Agents Market

4.1 Current Trends (2005-2010)

4.2 Market Forecast (2011-2016)

5. The US Dyslipidimia Market: Performance of Various Classes

5.1 Statins

5.1.1 Key Trends (2005-2010)

5.1.2 Share of Key Players

5.1.3 Sales & Forecast of Key Molecules

5.1.3.1 Atorvastatin (Lipitor) Historical Sales & Forecast

5.1.3.2 Rosuvastatin (Crestor) Historical Sales & Forecast

5.1.3.3 Simvastatin (Zocor) Historical Sales & Forecast

5.1.3.4 Pravastatin (Pravachol) Historical Sales & Forecast

5.1.3.5 Fluvastatin (Lescol) Historical Sales & Forecast

5.1.3.6 Lovastatin (Mevacor) Historical Sales & Forecast

5.1.3.7 Pitavastatin (Livalo) Historical Sales & Forecast

5.2 Fixed Dose Combinations

5.2.1 Key Trends

5.2.2 Share of Key Players

5.2.3 Sales & Forecast of Key Molecules

5.2.3.1 Ezetimibe/Simvastatin (Vyotrin) Historical Sales & Forecast

5.2.3.2 ER Niacin/Simvastatin (Simcor) Historical Sales & Forecast

5.2.3.3 Atorvastatin/Amlodipine (Caduet) Historical Sales & Forecast

5.2.3.4 ER Naicin/Lapropiprant (Tredaptive) Historical Sales & Forecast

5.2.3.1 Ezetimibe/Atorvastatin (MK-653C) Sales Forecast

5.2.3.2 ER Niacin/Laropiprant/Simvastatin (MK-0524B) Sales Forecast

5.3 Ion Exchange Resins

5.3.1 Key Trends

5.3.2 Share of Key Players

5.3.3 Sales & Forecast of Key Molecules

5.3.3.1 Colesevelam (Welchol) Historical Sales & Forecast

5.3.3.2 Cholestyramine (Questran) Historical Sales & Forecast

5.3.3.3 Colestipol (Colestid) Historical Sales & Forecast

5.4 Fibrates Market

5.4.1 Key Trends

5.4.2 Share of Key Players

5.4.3 Sales & Forecast of Key Molecules

5.4.3.1 Fenofibrate (Tricor) Historical Sales & Forecast

5.4.3.2 Fenofibric Acid (Trilipix) Historical Sales & Forecast

5.4.3.3 Gemfibrozil (Lopid) Historical Sales & Forecast

5.5 Other Cholesterol Triglyceride Regulators

5.5.1 Key Trends

5.5.2 Share of Key Players

5.5.3 Sales & Forecast of Key Molecules

5.5.3.1 Ezetimibe (Zetia) Historical Sales & Forecast

5.5.3.2 Nicotinic Acid (Niacin/Niaspan) Historical Sales & Forecast

5.6 Omega-3 Acid Ethyl Esters (Lovaza)

5.6.1 Key Trends

5.6.2 Share of Key Players

5.6.3 Sales Forecast

5.7 CETP Inhibitors

5.7.1 Sales Forecast for Key Molecules

5.7.1.1 Dalcetrapib (RO4607381/JTT-705) Sales Forecast

5.7.1.2 Anacetrapib (MK-0859) Sales Forecast

6. Genericization in the US Dyslipidemia Market

6.1 Generic Evolution in the US Dyslipidemia Market

6.2 Patent Expiries & Size of the Generic Opportunity

6.3 Forecast for Dyslipidemia Generics

7. Key Company Profile

7.1 Pfizer

7.2 Merck & Co

7.3 Astrazeneca

7.4 Abbott

7.5 Glaxosmithkline

To buy the complete report or to get a free sample:

Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America)

email:sales@imarcgroup.com

For more information please visit: